Organic Toroidal Array Apparatus of Making for Direct And Reagent-free Sensing of the Endotoxin Activities of a Single E. Coli Cell
20190137477 ยท 2019-05-09
Inventors
Cpc classification
G01N27/4161
PHYSICS
International classification
Abstract
The invented organic memristive and memcapacitive device comprises of arrayed cross-bar donut-shape toroidal matrix self-assembling membrane on an electrode mimicking mitochondria's double membrane and the direct electron-relay functions enables a bio-communication signal flow directly between endotoxin and the sensor at a single E. coli cell concentration under nature enzyme-free, antibody-free and reagent-free conditions. The sensor offers multiple functions for monitoring neuronal synapse pulse energy output under influence of Lipopolysaccharide (LPS) and other important biomarkers. The robust analytical performances of the device for monitoring endotoxins are important to human health.
Claims
1. A direct single endotoxin cell detecting device comprising: an electrode comprising a substrate of gold; a self-assembling membrane (SAM) comprising a polymer matrix comprised of an electrically conductive copolymer; wherein the copolymer is further comprised of: one or more first -cyclodextrin molecules having at least one or more acetyl groups; one or more polyethylene glycol polymers; one or more poly(4-vinylpyridine) polymers; one or more -cyclodextrin copolymers forming the SAM having a mitochondria-like surface structure comprising an array of nano islands; and the nano islands are vertically oriented and affixed on the substrate; an organic hydrophobic material forms an electron-relay network of (pnp).sub.n or (npn).sub.n with the function groups in the nano islands that mimics active sites of the electron-relaying of Fibroblast Growth Factor Receptor 1 (FGFR1) or choline acetyltransferase (CHAT).
2. According to claim 1, wherein the SAM of the device interacts with the organic hydrophobic material o-nitrophenyl acetate (o-NPA) formed an electron-relay network with TCD . . . PEG or TCD . . . PVP.
3. According to claim 2, wherein the device has a toroidal array dual sensing function of single molecule E. coli and Acetyl CoA.
4. According to claim 3, wherein the organic nanobiomimetic memristive/memcapacitive sensing apparatus have the nanometer air gap serving as the dielectric insulator between the electron-relay circuits.
5. According to claim 4, wherein the device directly measured and monitored endotoxin and its energy outcomes is Lipopolysaccharide (LPS) from E. coli in biological fluid under antibody-free, tracers-free, and reagent-free conditions using a double step chronopotentiometry (DSCPO) method, i.e., voltage method.
6. The use of the organic nanobiomimetic memristive/memcapacitive sensing apparatus according to claim 4, further includes procedures of applied a voltage or a current cross the MEA working electrode, as anode and a bare gold electrode as cathode, having another bare gold lead as the reference electrode, immersed in a biological media containing a target analyte, a changing currents flow or voltage change occurred in the sensor, that a signal intensity is recorded either in proportional or inversely proportional to the analyte concentration; wherein the target analyte can be detected and monitored by against the calibration curves.
7. According to claim 6, wherein the linear concentration range measured is up to 0.5 g/mL in 40 L specimen samples with a Detection of Limits (DOL) of 0.3 ng/mL having the energy density range between 123.2 and 0.11 WHr/cm.sup.3 using human milk specimens at 0.25 Hz and 10 nA with an imprecision value 3.0% (n=12) against 9.8 to 0.042 WHr/cm.sup.3 for organic milk samples using the voltage method.
8. According to claim 6, wherein the device direct measures and monitors intrinsic pM level of AcCoA and its energy outcomes in the biomimetic mitochondria cell of a single neuron in real-time with wide-band synapse frequencies from SWS to fast gamma ripples for monitoring milk quality and deficiencies using the double step chronopotentiometry (DSCPO) method, i.e., voltage method.
9. According to claim 6, wherein the device direct measured LPS concentration with a Detection of Limits (DOL) result is 1.210.sup.16 g LPS in 40 L milk samples on a 0.031 cm.sup.2 sensor under antibody-free and reagent-free conditions using the Chronoamperometry (CA) method.
10. According to claim 6, wherein the device direct measured AcCoA between the range 2 pM to 0.3 M by the CA method; it has a linear range from 2 pM to 0.4 nM. The value of Detection of Limits (DOL) is 1.210.sup.12 M/cm.sup.2.
11. According to claim 9, wherein the device direct measured AcCoA with a recovery value of 103%, and the method produced an error of less than 2% (n=12) by using milk samples.
12. According to claim 6, wherein the device is able to distinguish healthy High Frequency Oscillation (HFO) and Pathological High Frequency Oscillation (pHFO) formations through a contour energy map linked to LPS concentration in biological fluid, energy density and frequency from 50 ng/mL up to 1000 ng/mL from Rapid Eye Movement (REM) sleep frequency, fast gamma frequency to Sharp Wave-Ripple Complexes (SPW-R) frequency.
13. According to claim 6, wherein the device is a memristive/memcapacitive device with the non linear hysteresis loops vs. scan frequencies observed and the spontaneous discharge characteristics were observed between 0.11 WHr/cm.sup.3 to 123.2 WHr/cm.sup.3 inversely related to the LPS concentrations.
14. According to claim 13, wherein the device has potential application in superconducting device at zero-bias with 200 Hz scan rate in PBS solution with 1 A peak superconducting current.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
DETAILED DESCRIPTION OF THE INVENTION
Example 1Fabrication of the Nanostructure Self-Assembling Membrane (SAM) Gold Memristive/Memcapacitive Chips
[0037] The nanostructured biomimetic SAM was freshly prepared according to the published procedures based on cross linked conductive polymers of triacetyl--cyclodextrin (TCD), polyethylene glycol diglycidyl ether (PEG), poly(4-vinylpyridine) (PVP) and -CD copolymer with appropriate amount of propositions on gold chip [21-22]. The chemicals were purchased from Sigma and went through purification procedures before use. A mixture of o-nitrophenyl acetate (o-NPA) in a molar ratio 1000:1 to the TCD mixture was incubated for 2 hrs at 35 C.; then the mixture was injected onto the gold surface and incubated for 48 hrs at 35 C. After that, we followed the clean procedures for completion of the SAM fabrication [21-22].
Example 2Characterization of the Membrane
[0038] The morphology of the AU/SAM was characterized using an Atomic Force icroscope (AFM) (model Multimode 8 ScanAsyst, Bruker, Pa.). Data Collected in PeakForce Tapping Mode. Probes used were ScanAsyst-air probes (Bruker, Pa.). The silicon tips on silicon nitride cantilevers have 2-5 nm radius. The nominal spring constant 0.4 N/m was used.
Example 3Advantage of AcCoA's Rate Limiting Binding
[0039] Using the nano island structure SAM to mimic the function of Fibroblast Growth Factors Receptor-1 (FGFR-1) for improving fuel cell function was reported as shown in
Example 4Biomimetic Fibroblast Growth Factor Receptor 1 (FGFR1) SAM Membrane
[0040] FGFR1 is one of family receptors of tyrosine kinases. It plays important roles in embryonic development, angiogenesis, wound healing, and malignant transformation, bone development, and metabolism [35-36]. Y. Zhang's group reported mice with deleted FGFR1 exhibited an increased mobilization of endothelial progenitor cells (EPCs) into peripheral blood undergoing endotoximia, and the endotoximia was induced by injection of LPS [36]. Our project's initial step is to build a model device such that the device's SAM membrane mimics the FGFR1 receptor in the presence of LPS, which acts as a model metabolic product to access the FGFR1 function. By using this model to compare the effects of fresh human milk and organic cow milk at different frequencies of neuronal action/resting pulses at SWS and fast gamma frequency with or without LPS conditions to find out whether or not milk samples are energy efficiency or deficiency on the biomimetic brain cells will provide useful information to reveal which type of milk samples is immunologically advantage to infants.
Example 5Frequency Affects on Memristor/Memcapacitor's Performance
[0041] Evaluations of frequency's affect on memristor performance were conducted by Cyclic Voltammetric method (CV) in pH 7.0 saline solution at room temperature from a scan rate of 1 Hz to 1 KHz without using any biological specimen. Data are to be used for comparison between fresh human milk and USDA certified organic milk for infants with or without the presence of LPS covering the same range of real-time synapse action/resting potential pulses at different frequencies against controls.
[0042]
Example 6Quantitation of LPS Using the CA Method
[0043] Quantitation of LPS was conducted with two methods. The first was a Chronoamperometric (CA) method under two steps of fixed potential: 50 mV and 400 mV with each step duration of 100 ms, and the data rate is 20 kHz at room temperature under the conditions of antibody-free, radioactive tracer-free and reagent-free in certified organic milk for infants with seven LPS challenge levels from 5.0 pg/mL to 500 ng/mL against controls, each sample run triplicates.
[0044] The CA Method. The CA curve profiles were plotted using the biomimetic sensor in the presence of seven LPS concentration levels from 0, 5.0 pg/mL, 50.0 pg/mL, 5.0 ng/mL, 50 ng/mL, 125 ng/mL, and 250 ng/mL to 500 ng/mL against the control in organic milk samples as shown in
Example 7Quantitation of LPS Using the Voltage Method
[0045] The second quantitation method was the voltage method, i.e., the DSCPO method, and the conditions were the same as described in the section of Assessing Energy Outcomes under Challenges of LPS by using human milk and organic cow milk samples under 4-5 LPS challenges from 50 ng/mL to 1000 ng/mL, respectively at 10 A against controls at 0.25 and 200 Hz, respectively. Freshly obtained samples were without pretreatment. Human milk cooled by dry ice was delivered to the laboratory, and it was brought to room temperature naturally without any heating before spiking the LPS. All water used was autoclaved and double distillated from Fisher Scientific. LPS was purchased from Sigma, and it was dissolved in autoclaved and filtered PBS pH 7.0 buffers.
[0046] The Double Step Chronopotentiometry (DSCPO) method, as the voltage method, was used for assessing energy outcomes of slow-wave-sleeping (SWS) at 0.25 Hz and 200 Hz under the challenge of LPS at concentration ranges from 0, 50, 100, 500, to 1000 ng/mL of 4-5 levels with triplicates at 10 nA, respectively. Samples were tested at each level without prior sample preparation, such as dilution or heating. The experiments were conducted at room temperature. The milk samples compared were human milk and USDA certified organic cow milk for infants, with and without LPS. Human milk was collected from a normal subject who breastfeeds a 1 month-old newborn (Lee Biosolutions Corp.). An electrochemical workstation was used (Epsilon, BASi, IN) with a software package from BASi. OriginPro 2016 (Origin Lab Corp., MA) was used for all statistical data analysis and figure plotting.
[0047] Assessing energy outcomes was conducted by comparing human milk and certified organic milk, both with and without LPS, at 0.25 Hz and 200 Hz, respectively, using the voltage method.
[0048]
Example 8a Contour Mapping Method for Evaluation of Human Milk Immunological Advantage Under the LPS Challenge
[0049] The data obtained from the quantitation using the voltage method was used for evaluation of human milk immunological advantage under LPS challenges compared with that of the organic cow milk samples in 3D mapping method. The energy density results were put into the y column, the spiked LPS concentration over 0.0 to 1000 ng/mL was put into the x column, and the frequency was at the z column having two levels of 0.25 to 200 Hz. After converting the three data columns into a random XYZ correlation matrix, one can plot the contour maps and analyze the spatiotemporal formation of the pHFO, if it exists among human milk or organic milk samples. The real-time data obtained from the DSCPO method was converted to volumetric energy density, E=C.sub.s.Math.(V).sup.2/(23600), where C.sub.s is the specific volumetric capacitance, C.sub.s=[i.Math.t/V]/L, C.sub.s is in F/cm.sup.3 [33-34], t is the time in second, V is the voltage in V, i is the current in Amps, and L is the volume in cm.sup.3.
[0050] The energy density contour maps associated with the images are presented in
Example 9Evaluation of Immunological Advantage Under LPS Challenges
[0051] The comparisons of the immunological advantage under LPS challenges were evaluated through the study of the formation of the pHFO using a 3D energy density map method. The energy density results were put into the y column, the spiked LPS concentration over 0.0 to 1000 ng/mL put into the x column and the frequency was into z column having two levels of 0.25 to 200 Hz. After converting the three data columns into a random XYZ correlation matrix, one can plot the contour maps and analyze the spatiotemporal formation of the pHFO if a pHFO exists among human milk or organic milk samples.
Example 10Potential Application in Superconducting
[0052] According to
REFERENCES
[0053] [1]. P. O. Magalhaces, A. Mlopes, P. G. Mazzolas et. Al., J. of Pharm Pharmaceutical Sci 10(3), 388-404, 2007. [0054] [2]. M. Daneshiam, A. Guenther, A. Wendel et. al, J. of Immunological Methods 313, 169-175, 2006. [0055] [3]. Y. A. Knirel, M. A. Valvano, Bacterial (Eds), lipopolysaccharides, structure, chemical synthesis and interaction with host cells, Springer, 2011. [0056] [4]. T. Reimer, M. Brcic, M. Schweizer, T. W. Jungi, J. Leukocyte Biology, 83, 1249-1257, 2008. [0057] [5]. G. I. Tsiaoussis, S. F. Assimakopoulos et. al., World J. of Hepatology, 7(17), 2058-2068, 2015. [0058] [6]. LPS: the switch for inflammation in the gut and beyond, www.realfoodforager.com [0059] [7]. A. I. Petra, S. Panagiotidou, E. Haziagelaki, et. al., Clinical Therapeutics, 37(5), 984-995, 2015. [0060] [8]. Anna Struncka (ed), Cellular and molecular biology of autism spectrum disorders, Prague University Press. [0061] [9]. I. M. Chiu, B. A. Heeesters et. al., Nature 501, 52-57, 2013. [0062] [10]. B. Petschow, J. Dore, P. Hibberd, et. al., Annals of the New York Academy of Sceinces, 1306, 1-17, 2013. [0063] [11]. M. Lehmann, O. Wellnitz, R. M. Bruckmaier, J. of Diary Science, 96(2), 889-896, 2013. [0064] [12]. M. Lorna, A. Deleoz, K. M. Kalanetra, et. Al., J. of Proteome Research, 14, 491-502, 2015. [0065] [13]. Chapter five of breast feeding, J. of Tropical Pediatrics, Mother and Child Nutrition in Tropics and subtropics, World Health Organization: Breastfeeding: A brochure for ready reference, WHO, Geneva, 1981. [0066] [14]. N. Khaldi, V. Vijayakumar et al., J. Of Food Chem. 62, 7225-7232, 2014. [0067] [15]. M. L. Marin, R. Avrovo et. al., J. Pediatric. Castroenterol. Nutrition 49(3), 343-348, 2009. [0068] [16]. E. T. Chen, J. Thorten, C. Ngatchou, S-H Duh, P. T. Kissinger, NSTi-NanoTech 2, 107-110, 2013. [0069] [17]. E. T. Chen, J. T. Thornton and C. Mulchi, Jr., Sensors and Transducers Journal, 191(8), 84-99, 2015. [0070] [18]. J. T. Thornton, C. Mulchi Jr, P. T. Kissinger, E. T. Chen, Sensors and Transducers Journal, 191(8), 100-113, 2015. [0071] [19]. E. T. Chen, J. Thornton, C. Ngatchou and S-H Duh, NSTi-Nanotech, 2, 169-172, 2014. [0072] [20]. S. H. Duh, J. T. Thornton, P. T. Kissinger and E. T. Chen, Biotech, Biomaterials and Biomedical: TechConnect Briefs, 172-175, 2015. [0073] [21]. U-M. Bilhardt, P. Stein and G. M. Whitesides, Bioorganic Chemistry, 17, 1-12, 1989. [0074] [22]. A. B. A. Prempeh, A. K. Prince and E. G. J. Hide, Biochem. J. 129, 991-994, 1972. [0075] [23]. T. Kato, J. of Neurochemistry, 42 (4), 903-909, 1984. [0076] [24]. A-R. Kim, R. j. Rylett, B. H. Shilton, Biochemistry, 45, 14621-14631, 2006. [0077] [25]. A. Szutowicz, H. Bielarczyk, A. Jankowska-Kulawy, T. Pawetczyk, A. Ronowsa, Neurochem Res, 38, 1523-1542, 2013. [0078] [26]. Y. Tsuchiya, U. Pham, W. Hu, S-I Ohnuma, I. Gout, PLOS One, 9(5), e97693, 2014. [0079] [27]. Y. Oda, Pathology International 49, 921-937, 1999. [0080] [28]. D. Wu and L. B. Hersh, J. Neurochemistry, 62, 1653-1663, 1994. [0081] [29]. T. Merno-Ramos, A. Vazquez-Calvo, J. Cacas, et. Al., Antimicrobial agent and chemotherapy, 60, 307-315, 2015. Doi:10.1128/AAC.01578-15. [0082] [30]. J. J. Kamphorst, M. K. Chung, J. Fan, J. D. Rabinowitz, Cancer and metabolism, 2(23), 1-8, 2014. [0083] [31]. W-P Lu, S. W. Ragsdale, J. Biol. Chem, 266(6), 3554-3564, 1991. [0084] [32]. M. Riera-Borrull, E. Rodriguez-Gallego, A. Hernandez-Aguilera et al., J. Am. Soc. Mass Spectrom, 2015. DOI: 10.1007/s1336-1-015-1262-3. [0085] [33]. E. T. Chen, J. Thornton, C. Ngatchou, S-H. Duh, P. T. Kissinger, NSTi-Nanotech, (3), 115-118, 2013. [0086] [34]. E. T. Chen and C. Ngatchou, Clean Technology (3), 204-207, 2011. [0087] [35]. M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, Science 276, 955-959, 1997. [0088] [36]. Y. Zhang, N. Su, F. Luo et. al., Int. J. Biol. Sci, 10(9), 1064-1071, 2014. [0089] [37]. J. Martinez-Rincon, M. D. Ventra, Y. V. Pershin, Physical Review B, 81(19), 195430-1-195430-7, 2010. [0090] [38]. M. D. Pickett, G. Medeiros-Ribeiro and R. S. Williams Nature Materials, DOI: 10.1038/NMAT3510, 2012. [0091] [39]. R. Kozma, R. E. Pino, G. E. Pazienza, Advances in neuomorphic memristor science and applications, Springer Publisher, 2012. [0092] [40]. M. D. Ventra, Y. V. Pershin, Nanotechnology 24, 255201, 2013.